Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Plasma cell 1Gynecologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 7Colonic Neoplasms 5Rectal Neoplasms 4Breast Neoplasms 4Solitary Fibrous Tumor, Pleural 3Mesothelioma, Malignant 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms, Male 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinoma 1

Interventions

pembrolizumab 39Nivolumab 13Cisplatin 12Paclitaxel 11Docetaxel 11Carboplatin 10atezolizumab 9Trastuzumab 9Gemcitabine 9Cyclophosphamide 8fludarabine 7Bevacizumab 7aldesleukin 6durvalumab 5Taxes 5Oxaliplatin 5Magnetic Resonance Spectroscopy 5Leucovorin 5Irinotecan 5Fluorouracil 5130-nm albumin-bound paclitaxel 5avelumab 4Specimen Handling 4Psychiatric Rehabilitation 4Ipilimumab 4Drug Therapy 4Cetuximab 4Capecitabine 4Albumin-Bound Paclitaxel 4tislelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × cediranib × Thoracic × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡